 CAMBRIDGE, Mass. BEIJING, China--BUSINESS WIRE--- BGNE BTKi--BeiGene, Ltd. NASDAQ: BGNE; HKEX: 06160, a global, science-driven biotechnology company, today announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing BRUKINSA zanubrutinib to bendamustine and rituximab BR in patients with treatment-naïve TN chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL whose tumor did not exhibit the deletion of chromosome 17p13.1 del17p. With a 